Truist Financial Has Lowered Expectations for Organogenesis (NASDAQ:ORGO) Stock Price

Organogenesis (NASDAQ:ORGO - Get Free Report) had its price target dropped by investment analysts at Truist Financial from $3.00 to $2.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a "hold" rating on the stock. Truist Financial's price objective would suggest a potential upside of 14.16% from the stock's current price.

A number of other equities research analysts have also weighed in on the stock. UBS Group set a $3.00 price target on shares of Organogenesis in a report on Thursday, May 28th. Wall Street Zen upgraded shares of Organogenesis from a "strong sell" rating to a "sell" rating in a report on Saturday, June 20th. Weiss Ratings cut shares of Organogenesis from a "hold (c)" rating to a "sell (d)" rating in a research report on Monday, May 11th. Finally, BTIG Research lowered Organogenesis from a "buy" rating to a "neutral" rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Organogenesis presently has a consensus rating of "Hold" and an average target price of $5.50.

Read Our Latest Stock Analysis on ORGO

Organogenesis Trading Down 27.3%

Shares of ORGO opened at $1.75 on Friday. The stock has a market cap of $225.45 million, a PE ratio of -9.52 and a beta of 1.34. Organogenesis has a 12 month low of $1.99 and a 12 month high of $7.08. The stock's 50-day moving average is $2.44 and its two-hundred day moving average is $2.77. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.53 and a quick ratio of 3.16.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.36). The firm had revenue of $43.76 million during the quarter, compared to analyst estimates of $54.27 million. Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%.

Institutional Trading of Organogenesis

Several institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in Organogenesis during the 1st quarter worth $105,000. Creative Planning lifted its position in shares of Organogenesis by 84.5% during the second quarter. Creative Planning now owns 35,392 shares of the company's stock worth $130,000 after purchasing an additional 16,205 shares during the last quarter. Cetera Investment Advisers bought a new position in shares of Organogenesis during the second quarter worth about $222,000. American Century Companies Inc. grew its stake in Organogenesis by 25.6% in the second quarter. American Century Companies Inc. now owns 164,793 shares of the company's stock worth $603,000 after purchasing an additional 33,573 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Organogenesis by 36.6% in the second quarter. Russell Investments Group Ltd. now owns 168,152 shares of the company's stock valued at $617,000 after buying an additional 45,021 shares during the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

About Organogenesis

(Get Free Report)

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.

Read More

• Five stocks we like better than Organogenesis
• IonQ Sparks a Quantum Grid Revolution
• No Hangover: Revisiting Microsoft One Week After Earnings
• Western Digital Stock Falls 12% Despite Beating Earnings Estimates
• One Comment on CVS's Earnings Call Sent the Stock Tumbling

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Organogenesis Right Now?

Before you consider Organogenesis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.

While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here